Home
KAPA
KAPA News

Latest KAIROS PHARMA LTD (KAPA) News on July 9, 2025

Business Wire

a month ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Newsfile

2 months ago

Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference

Business Wire

2 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Business Wire

3 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Business Wire

3 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls

TipRanks

3 months ago

Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls

Business Wire

3 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105

Newsfile

3 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105

Business Wire

3 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Business Wire

4 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Business Wire

4 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma

Business Wire

5 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Business Wire

5 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Business Wire

5 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma

Business Wire

5 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Business Wire

6 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Business Wire

6 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

ACCESSWIRE

7 months ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Business Wire

7 months ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Kairos Pharma Approved to Dual List on Upstream

GlobeNewswire

8 months ago

Kairos Pharma Approved to Dual List on Upstream

GlobeNewswire

9 months ago

Kairos Pharma to Present at the LD Micro Main Event XVII

GlobeNewswire

9 months ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

9 months ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

GlobeNewswire

10 months ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

GlobeNewswire

10 months ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Share on Social Networks: